RNO logo

Rhinomed Stock Price

Symbol: ASX:RNOMarket Cap: AU$11.5mCategory: Pharmaceuticals & Biotech

RNO Share Price Performance

AU$0
0.00 (0.00%)
AU$0
0.00 (0.00%)
Sorry, there is currently no price data for this company.

RNO Community Narratives

There are no narratives available yet.

RNO Community Fair Values

    Recent RNO News & Updates

    No updates

    Rhinomed Limited Key Details

    AU$8.1m

    Revenue

    AU$2.8m

    Cost of Revenue

    AU$5.3m

    Gross Profit

    AU$16.2m

    Other Expenses

    -AU$10.9m

    Earnings

    Last Reported Earnings
    Jun 30, 2023
    Next Reporting Earnings
    n/a
    Earnings per share (EPS)
    -0.038
    Gross Margin
    65.53%
    Net Profit Margin
    -135.49%
    Debt/Equity Ratio
    -90.4%

    Rhinomed Limited Competitors

     
     
     
     
     
     
     
     
     
     
     
     

    About RNO

    Founded
    2004
    Employees
    n/a
    CEO
    Michael Johnson
    WebsiteView website
    www.rhinomed.global

    Rhinomed Limited engages in the research, development, and commercialization of consumer and medical devices worldwide. The company offers wearable nasal technology that improve breathing, sleeping, and maintaining health and diagnose disease. Its products include Turbine for enhanced breathing in sports; Mute, which helps to breath more and snore less; Pronto, a vapor inhaler to improve airflow and better sleep; and Rhinoswab that is used to collect a nasal swab. The company also engages in developing programs in various markets, including sleep and sleep architecture, the impact of sleep and respiratory, function on cognitive issues, obstructive sleep apnea, pain, nausea, respiratory disease, and diagnostics and sensors; and offers a drug delivery platform for the delivery of cannabinoid formulations. The company was formerly known as Consegna Group Limited and changed its name to Rhinomed Limited in November 2013. Rhinomed Limited was incorporated in 2004 and is based in Cremorne, Australia.

    Australian Market Performance

    • 7 Days: 0.7%
    • 3 Months: 7.6%
    • 1 Year: 14.0%
    • Year to Date: 6.4%
    Over the last 7 days, the market has remained flat, although notably the Consumer Discretionary sector gained 3.1% in that time. More promisingly, the market is up 14% over the past year. As for the next few years, earnings are expected to grow by 11% per annum. Market details ›
    This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
    Continue reading